SEC Filing Document

Company: BIOVENTRIX, INC.
Ticker: 
CIK: 1283259
Filing Type: S-1/A
Document Type: S-1/A
Date Filed: 2026-03-18
Accession Number: 0001493152-26-010642
Exchange: 
SIC Code: 3841
SIC Description: Surgical & Medical Instruments & Apparatus
URL: https://www.sec.gov/Archives/edgar/data/1283259/000149315226010642/forms-1a.htm

Chunk 78 of 85
Word Count: 1413
Character Count: 9446

Document Content:

date. Of the total options granted, 103,250 vested in 2025 and the remaining 309,750 vest in equal monthly installments through December 2028, subject to continued service. The options are equity-classified awards. The weighted-average grant-date fair value of the options was $0.39 per share, resulting in an aggregate grant-date fair value of $159,808. The fair value was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility of 50%, expected term of 6 years, risk-free interest rate of 4.62%, and an expected dividend yield of 0%. The Company recognized $39,952 of stock-based compensation expense related to these options during the year ended December 31, 2025, which was recorded in selling, general and administrative expenses. As of December 31, 2025, total unrecognized compensation cost related to unvested stock options was $119,856, which is expected to be recognized over a weighted-average remaining vesting period of 3.0 years. See Note 7.

February 2025, the Company granted 85,000 incentive stock options to employees under the Company’s equity incentive plan. The options
have an exercise price equal to the fair value of the Company’s common stock on the grant date. Of the total options granted, 19,479
vested in 2025 and the remaining 65,521 vest in equal monthly installments through January 2029, subject to continued service. The options
are equity-classified awards.

The
weighted-average grant-date fair value of the options was $0.39 per share, resulting in an aggregate grant-date fair value of $32,776.
The fair value was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility
of 50%, expected term of 6 years, risk-free interest rate of 4.52%, and an expected dividend yield of 0%.

BIOVENTRIX,
INC.

Notes
to Consolidated Financial Statements

December
31, 2025 and 2024

The
Company recognized $7,511 of stock-based compensation expense related to these options during the year ended December 31, 2025, which
was recorded in selling, general and administrative expenses. As of December 31, 2025, total unrecognized compensation cost related to
unvested stock options was $25,265, which is expected to be recognized over a weighted-average remaining vesting period of 3.1
years.

April 2025, the Company filed Certificate of First Amendment of Certificate of Designations of Series A-1 Preferred Stock increasing
the amount of authorized shares designated as Series A-1 Preferred Stock from 1,200,000 shares to 3,000,000 shares from the Company’s
authorized Blank Check Preferred Stock.

May 2025, the remaining 96,225 of restricted common stock awards issued in September 2024 became fully vested.

June 2025, the Company granted 30,000 incentive stock options to employees under the Company’s equity incentive plan. The options
have an exercise price equal to the fair value of the Company’s common stock on the grant date. Of the total options granted, 3,750
vested in 2025 and the remaining 26,250 vest in equal monthly installments through May 2029, subject to continued service. The options
are equity-classified awards.

The
weighted-average grant-date fair value of the options was $0.38 per share, resulting in an aggregate grant-date fair value of $11,496.
The fair value was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility
of 50%, expected term of 6 years, risk-free interest rate of 4.34%, and an expected dividend yield of 0%.

The
Company recognized $1,437 of stock-based compensation expense related to these options during the year ended December 31, 2025, which
was recorded in selling, general and administrative expenses. As of December 31, 2025, total unrecognized compensation cost related to
unvested stock options was $10,059, which is expected to be recognized over a weighted-average remaining vesting period of 3.5
years.

August 2025, the Company filed Certificate of Second Amendment of Certificate of Designations of Series A-1 Preferred Stock increasing
the amount of authorized shares designated as Series A-1 Preferred Stock from 3,500,000 shares to 5,500,000 shares the Company’s
authorized Blank Check Preferred Stock.

October 2025, the Company granted 177,500 incentive stock options to officers and employees under the Company’s equity incentive
plan. The options have an exercise price equal to the fair value of the Company’s common stock on the grant date. Of the total
options granted, 11,094 vested in 2025 and the remaining 166,406 vest in equal monthly installments through September 2029, subject to
continued service. The options are equity-classified awards. See Note 7.

BIOVENTRIX,
INC.

Notes
to Consolidated Financial Statements

December
31, 2025 and 2024

The
weighted-average grant-date fair value of the options was $0.60 per share, resulting in an aggregate grant-date fair value of $105,561.
The fair value was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility
of 50%, expected term of 6 years, risk-free interest rate of 4.12%, and an expected dividend yield of 0%.

The
Company recognized $6,604 of stock-based compensation expense related to these options during the year ended December 31, 2025, which
was recorded in selling, general and administrative expenses. As of December 31, 2025, total unrecognized compensation cost related to
unvested stock options was $99,057, which is expected to be recognized over a weighted-average remaining vesting period of 3.8
years.

October 2025, the Company granted 245,000 non-qualified stock options to members of the board of directors, consultants and an officer
under the Company’s equity incentive plan. The options have an exercise price equal to the fair value of the Company’s common
stock on the grant date. Of the total options granted, 15,313 vested in 2025 and the remaining 229,687 vest in equal monthly installments
through September 2029, subject to continued service. The options are equity-classified awards. See Note 7.

The
weighted-average grant-date fair value of the options was $0.60 per share, resulting in an aggregate grant-date fair value of $145,842.
The fair value was estimated using the Black-Scholes option-pricing model with the following weighted-average assumptions: expected volatility
of 50%, expected term of 6 years, risk-free interest rate of 4.12%, and an expected dividend yield of 0%.

The
Company recognized $9,115 of stock-based compensation expense related to these options during the year ended December 31, 2025, which
was recorded in selling, general and administrative expenses. As of December 31, 2025, total unrecognized compensation cost related to
unvested stock options was $136,727, which is expected to be recognized over a weighted-average remaining vesting period of 3.8
years.

a result of the above transactions, total shares as of December 31, 2025, were as follows:

Class
of Security Shares
Authorized Shares
Outstanding Shares
Available

Common 23,500,000 5,712,615 17,787,385

Common Stock Options 1,500,000 950,500 549,500

Series A Preferred 6,000,000 1,565,000 4,435,000

Series A-1 Preferred 5,500,000 - 5,500,000

Blank
Check Preferred 1,000,000 - 1,000,000

December

BIOVENTRIX,
INC.

Notes
to Consolidated Financial Statements

December
31, 2025 and 2024

Rights
and Preferences of Preferred Shareholders

Dividends
– Holders of preferred stock are entitled to receive dividends whenever funds are legally
available and when declared by the Board of Directors, subject to the prior rights of holders of all classes of stock outstanding. The
holders of the Series A preferred stock are not entitled to cumulative dividends. No dividends have been declared by the board of directors
as of December 31, 2025.

Liquidation
Rights – In the event of any liquidation, dissolution, or winding-up of the Company, each holder of Series A preferred stock
is entitled to receive a liquidation preference amount equal to one times the original issue price plus any dividends declared but unpaid.
After payment of the full liquidation preference to holders of preferred stock the remaining assets of the Company legally available
for distribution shall be distributed ratably to the holders of the common stock.

Conversion
– Each share of preferred stock is convertible at the option of the holder into shares of common stock (subject to adjustment
for certain events, including dilutive issuances, stock splits, and reclassifications) at a conversion price originally equal to the
original issue price subject to certain adjustments.

Mandatory
Conversion, Series A Preferred Stock – Upon an IPO with gross proceeds of $7,500,000
or more, the Series A Preferred Stock is subject to immediate mandatory conversion into Common Stock at a conversion rate equal to the
greater of (A) the then effective conversion rate (defined as the Series A Original Issue Price divided by the Series A Conversion Price)
or (B) one times (1x) the Original Issue Price of the Series A Preferred Stock divided by the price per share of the Common Stock issued
in this offering. For Series A preferred shares, the original issue price is $10.00 per share and the current conversion price is $10.00
per share subject to adjustment for stock splits and other forms of recapitalization.